Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an…
GA Depot
A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
Recommended Posts
- Researchers identify new therapeutic targets to combat MS progression
- Being prepared for the stress of MS may help to manage it
- Guest Voice: An open letter to MS about snowflakes that meet chameleons
- MS relapses rare after age 60 whether DMTs continued or stopped
- Teenagers who eat a healthy diet face less risk of later MS, study suggests